PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer …
R Aggarwal, G Heller, DW Hillman, H Xiao… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate …
PRESTO Study Investigators - Journal of Clinical Oncology, 2024 - experts.illinois.edu
PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate …
R Aggarwal, G Heller, DW Hillman, H Xiao… - Journal of Clinical …, 2024 - europepmc.org
Patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy
and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen …
and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen …
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate …
R Aggarwal, G Heller… - … official journal of …, 2024 - digitalcommons.providence.org
PURPOSE: Patients with biochemically recurrent prostate cancer (BRPC) after radical
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate …
R Aggarwal, G Heller, DW Hillman… - Journal of Clinical …, 2024 - ingentaconnect.com
PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate …
PRESTO Study Investigators - Journal of Clinical …, 2024 - mayoclinic.elsevierpure.com
PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate …
PRESTO Study Investigators - Journal of Clinical …, 2024 - einstein.elsevierpure.com
PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate …
R Aggarwal, G Heller, DW Hillman… - Journal of clinical …, 2024 - pubmed.ncbi.nlm.nih.gov
Purpose Patients with biochemically recurrent prostate cancer (BRPC) after radical
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate …
PRESTO Study Investigators - Journal of Clinical …, 2024 - providence.elsevierpure.com
PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate …
PRESTO Study Investigators - Journal of Clinical Oncology, 2024 - profiles.wustl.edu
PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …
prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide …